Liza Takiya | Dermatology | Business and Academic Collaboration Award

Posted on by ScienceFather

Dr. Liza Takiya | Dermatology | Business and Academic Collaboration Award

Senior Medical Director. Pfizer, United States

A seasoned professional with over 25 years of experience in clinical internal medicine and the pharmaceutical industry, specializing in dermatology, rheumatology, neuroscience, pain management, and women’s health. Known for scientific leadership in medical strategy planning and execution, including product launches and advisory boards.  Recognized for building relationships, strategic thinking, and delivering results, leading to multiple awards and promotions throughout a distinguished career.

Profile

scopus

Education🎓

Doctor of Pharmacy from the University of Maryland, 1997.  Completed an ASHP Accredited Ambulatory Care/Community Practice Residency at the University of Maryland School of Pharmacy, 1997-1998.  Pre-Pharmacy studies at the University of Maryland, College Park, 1991-1993.  Participated in numerous management and leadership training programs, enhancing skills in executive coaching and women in leadership.

Experience💼 

Currently a Senior Director of US Medical Affairs in Dermatology at Pfizer Inc., with previous roles in Global Product Development and various leadership positions in Medical Affairs.  Served as an Associate Professor of Clinical Pharmacy at the University of the Sciences in Philadelphia, fostering the next generation of pharmacy leaders. 🏥 Prior experience includes roles at CVS Pharmacy, enhancing clinical pharmacy practice across Maryland and Pennsylvania.

Awards and Honors🏆

Fellow of the College of Clinical Pharmacy, awarded in 2010. 🌟 Completed multiple prestigious leadership programs, including the LandIt Executive Coaching in 2021 and Florida International University Women Leaders Program in 2020.  Received various internal awards for exemplary performance and contributions in medical affairs at Pfizer. 🎖 Recognized for her commitment to advancing women’s leadership in pharmacy and healthcare.

Research Focus🔬

Focused on medical strategy development and execution in dermatology, rheumatology, and neuroscience.  Research interests include product launches, field training, medical content creation, and clinical guidelines.  Committed to enhancing patient care through innovative pharmaceutical solutions and impactful educational initiatives.  Engages in community development through research and training aimed at addressing healthcare disparities.

Conclusion

In summary, the candidate is highly suitable for the Research for Business and Academic Collaboration Award due to their extensive clinical and pharmaceutical experience, demonstrated leadership, and commitment to education. While there are areas for improvement, such as expanding their research network and enhancing publication efforts, their strengths outweigh these areas. The candidate’s potential to drive impactful collaborations between academia and industry makes them a deserving nominee for this award.

Publication

1. Efficacy and Safety of Ritlecitinib in Alopecia Totalis and Alopecia Universalis

Authors: Mesinkovska, N., King, B., Zhang, X., Wolk, R., Schaefer, G.
Journal: Journal of Dermatology, 2024
Overview: This study evaluates the efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, specifically in adolescents and adults suffering from alopecia totalis and universalis. The findings indicate promising outcomes in hair regrowth and tolerability, marking a significant advancement in treatment options for severe forms of alopecia.
Citations: 0

2. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata

Authors: Hordinsky, M., Hebert, A.A., Gooderham, M., Wolk, R., Tran, H.
Journal: Pediatric Dermatology, 2023, 40(6), pp. 1003–1009
Overview: This article reports on the results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial, highlighting the effectiveness of ritlecitinib in treating adolescents with alopecia areata. The study reveals significant improvements in hair regrowth compared to the placebo group.
Citations: 14

3. Overview of Alopecia Areata for Managed Care and Payer Stakeholders

Authors: King, B., Pezalla, E., Fung, S., Takiya, L., Napatalung, L.
Journal: Journal of Managed Care and Specialty Pharmacy, 2023, 29(7), pp. 848–856
Overview: This review addresses the implications of alopecia areata from a managed care perspective, discussing treatment options, economic considerations, and the importance of awareness among payer stakeholders regarding the condition.
Citations: 1

4. Impact of Crisaborole on Sleep Outcomes in Pediatric Patients

Authors: Fowler, J., Sugarman, J., Sher, L., Marfo, A.A., Takiya, L.
Journal: Dermatology and Therapy, 2023, 13(4), pp. 951–960
Overview: This study assesses the effects of Crisaborole, a topical medication, on sleep quality in pediatric patients with mild-to-moderate atopic dermatitis. The findings suggest that treatment with Crisaborole may lead to improved sleep outcomes in this demographic.
Citations: 2

5. Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment

Authors: Senna, M., Forman, S., Bordone, L., Ahmed, H.M., Takiya, L.
Journal: SKIN: Journal of Cutaneous Medicine, 2023, 7(4), pp. s224
Overview: This post hoc analysis of the ALLEGRO trial examines hair regrowth in specific areas among patients who did not meet target efficacy responses at Week 24. The results indicate that continued treatment with ritlecitinib may still yield positive hair regrowth outcomes in these patients.
Citations: 0

6. Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis by Baseline BMI

Authors: Dikranian, A.H., Gonzalez-Gay, M.A., Wellborne, F., Tatulych, S., Curtis, J.R.
Journal: RMD Open, 2022, 8(1)
Overview: This article analyzes pooled data from phase 3 studies to assess how baseline body mass index (BMI) affects the efficacy of tofacitinib in treating rheumatoid arthritis, emphasizing the need for personalized treatment approaches.
Citations: 12

7. Efficacy and Safety of Tofacitinib by Background Methotrexate Dose

Authors: Kivitz, A.J., FitzGerald, O., Nash, P., Wang, C., Takiya, L.
Journal: Clinical Rheumatology, 2022, 41(2), pp. 499–511
Overview: This post hoc exploratory analysis examines the relationship between background methotrexate dosage and the efficacy and safety of tofacitinib in patients with psoriatic arthritis, aiming to optimize treatment strategies.
Citations: 8

8. Patient and Caregiver Preferences on Treatment Attributes for Atopic Dermatitis

Authors: Ervin, C., Crawford, R., Evans, E., Takiya, L., Myers, D.E.
Journal: Journal of Dermatological Treatment, 2022, 33(4), pp. 2225–2233
Overview: This study investigates the preferences of patients and caregivers regarding treatment characteristics for atopic dermatitis, highlighting the importance of patient-centered approaches in therapeutic decision-making.
Citations: 13

9. Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use

Authors: Geng, B., Hebert, A.A., Takiya, L., Sanders, P., Lebwohl, M.G.
Journal: Dermatology and Therapy, 2021, 11(5), pp. 1679
Overview: An erratum correcting previously published results on the long-term efficacy and safety of Crisaborole in patients with mild-to-moderate atopic dermatitis.
Citations: 0

10. Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use

Authors: Geng, B., Hebert, A.A., Takiya, L., Sanders, P., Lebwohl, M.G.
Journal: Dermatology and Therapy, 2021, 11(5), pp. 1667–1678
Overview: This article reviews the long-term use of Crisaborole in patients aged ≥ 2 years with mild-to-moderate atopic dermatitis, assessing both efficacy and safety profiles.
Citations: 6